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MouseWe examined the individual and combined effects of teriparatide and anti-RANKL (receptor activator of
nuclear factor κB ligand) monoclonal antibody in ovariectomized mice. Three-month-old female C57BL/6 mice
were ovariectomized (OVX) or sham operated. Four weeks after OVX, they were assigned to 3 different groups
to receive anti-RANKL monoclonal antibody (Ab) alone (5 mg/kg single injection at 4 weeks after OVX, Ab
group), teriparatide alone (80 μg/kg daily injection for 4 weeks from 4 weeks after OVX, PTH group), or mAb
plus teriparatide (Ab + PTH group). Mice were sacriﬁced 8 weeks after OVX. Bone mineral density (BMD) was
measured at the femur and lumbar spine. Hind limbs were subjected to histological and histomorphometric analy-
sis. Serum osteocalcin and CTX-I levels were measured to investigate the bone turnover. Compared with Ab group,
Ab+ PTH group showed a signiﬁcant increase in BMD at distal femur and femoral shaft. Cortical bone volumewas
signiﬁcantly increased in PTH and Ab + PTH groups compared with Ab group. Bone turnover in Ab + PTH group
was suppressed to the samedegree as in Ab group. The number of TRAP-positivemultinucleated cellswasmarkedly
reduced in Ab and Ab + PTH groups. These results suggest that combined treatment of teriparatide with
anti-RANKL antibody has additive effects on BMD in OVX mice compared with individual treatment.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Skeletal homeostasis ismaintained in a strictly regulated balance be-
tween bone resorption and bone formation (Baron, 1989; Boyle et al.,
2003; Harada and Rodan, 2003). Osteoclasts are multinucleated giant
cells of hematopoietic origin and are responsible for both physiologic
and pathologic bone resorption (Roodman, 1999, 2004; Tanaka, 2007;
Takayanagi et al., 2000). Receptor activator of nuclear factor κB ligand
(RANKL) is a member of the tumor necrosis factor (TNF) superfamily
cytokine and plays an essential role in the differentiation, function,
and survival of osteoclasts (Lacey et al., 1998; Yasuda et al., 1998). The
essential role of RANKL in osteoclastogenesis and bone resorption has
been established by the ﬁndings that the targeted disruption of RANKL
or its receptor RANK induced osteopetrosis in mice due to an impaired
osteoclast differentiation (Dougall et al., 1999; Kong et al., 1999),
while knockout of osteoprotegerin (OPG), a physiologic inhibitor of
RANKL, induced severe osteoporosis caused by increased bone resorp-
tion by osteoclasts (Mizuno et al., 1998). RANKL–RANK pathways are
also involved in pathologic bone loss such as postmenopausal osteopo-
rosis, rheumatoid arthritis, and metastatic bone diseases (Takayanagi-ku, Tokyo 113-0033, Japan.
aka).et al., 2000; Roodman, 2004). Therefore, regulating the RANKL–RANK
pathway is one of the best therapeutic approaches to conquer these
pathological conditions (Tanaka et al., 2005).
Denosumab is a fully human monoclonal antibody that speciﬁcally
binds to human RANKL and strongly inhibits its interaction with RANK
(Bekker et al., 2004; McClung et al., 2006; Lewiecki et al., 2007). Subcu-
taneous administration of 60mgdenosumab every 6months resulted in
a rapid reduction of bone turnover and a signiﬁcant increase in bone
mineral density (BMD) in postmenopausal women with low bone
mass (McClung et al., 2006). In addition, denosumab signiﬁcantly
reduced vertebral, nonvertebral, and hip fracture risks in women with
postmenopausal osteoporosis compared with placebo in the pivotal
3 year FREEDOM trial (Cummings et al., 2009).
On the other hand, intermittent injection of teriparatide (recombi-
nant human PTH [1–34], PTH), is the only bone anabolic agent currently
available for the treatment of osteoporosis. The precise mechanisms
how PTH increases bone formation in vivo still remains elusive, but
previous studies have shown that osteoclasts may be required for the
anabolic effect of PTH (Black et al., 2003; Finkelstein et al., 2003).
There has been a controversy regarding the combination therapy of
teriparatide and anti-resorptive agents such as bisphosphonates.
Previous clinical studies have indicated that amino bisphosphonate
treatment does not augment the anabolic effect of PTH (Finkelstein
et al., 2003, 2006; Tsai et al., 2013). However, recent clinical study
Fig. 1. Experimental protocol.Micewere assigned to ﬁve different groups (n=5–6). Four groupswere ovariectomized (OVX), and one groupwas shamoperated and remained untreated
for 4 weeks after the operation. Four weeks after surgery, treatment with anti-RANKLmAb (5 mg/kg s.c., once at 4 weeks after OVX), PTH (80 μg/kg/day s.c., daily injection for 4 weeks),
or Ab plus PTH was started in the OVX groups. All mice were sacriﬁced 8 weeks after operation.
Fig. 2. Effect of anti-RANKLmonoclonal antibody on the anabolic effect of PTH. (A) Representativemicro CT of the distal femur of the sham, OVX, Ab, PTH, and Ab+PTH groups at 8weeks
after surgery. Scale bars: 800 μm. (B) BMD of the distal femur at 8 weeks after surgery, i.e., after 4 weeks of treatment with anti-RANKL mAb, PTH, or Ab + PTH. (a) p b 0.01 vs. Sham,
(b) p b 0.01 vs. OVX, (c) p b 0.01 vs. Ab, (d) p b 0.01 vs. PTH. (C) BMD of the femoral shaft at 8 weeks after surgery, i.e., after 4 weeks of treatment with anti-RANKL mAb, PTH,
or Ab + PTH. (a) p b 0.01 vs. Sham, (b) p b 0.01 vs. OVX, (c) p b 0.01 vs. Ab. (D) BMD of the lumbar spine at 8 weeks after surgery, i.e., after 4 weeks of treatment with anti-RANKL
mAb, PTH, or Ab + PTH. (a) p b 0.05 vs. Sham, (b) p b 0.05 vs. OVX. Data are shown as the mean ± SD (n= 5–6).
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Fig. 3. Serum concentration of bonemetabolicmarkers. (A) SerumCTX-I. (B) Serum osteocalcin. (a) p b 0.01 vs. Sham, (b) p b 0.01 vs. OVX, (c) p b 0.01 vs. Ab, (d) p b 0.01 vs. PTH. Data are
mean ± SD (n= 5–6).
Fig. 4. Distal femur stained with toluidine blue or TRAP. Decalciﬁed sections of distal femur in sham, OVX, Ab, PTH, or Ab + PTH group stained with toluidine blue are shown at low
magniﬁcation (left panel) and higher magniﬁcation (middle panel). Bars: 100 μm (left) and 50 μm (middle). Decalciﬁed sections of distal femur in sham, OVX, Ab, PTH, or Ab + PTH
group stained with TRAP (right panel). Bar: 20 μm.
3N. Tokuyama et al. / Bone Reports 2 (2015) 1–7
4 N. Tokuyama et al. / Bone Reports 2 (2015) 1–7demonstrated the additive effects of denosumab on PTH-induced BMD
increase (Tsai et al., 2013) although previous animal studies of combi-
nation of RANKL inhibitors and PTH have not shown consistent results
(Furuya et al., 2011; Samadfam et al., 2007). In this study, we examined
the effect of combined anti-RANKL monoclonal antibody and PTH in
ovariectomized mice to uncover themechanism of action of the combi-
nation therapy.
2. Materials and methods
2.1. Reagents and animals
Anti-murine monoclonal RANKL antibody (OYC1, hereinafter re-
ferred to Ab, Orient Yeast Co., Tokyo, Japan) was obtained as previouslyFig. 5. Bone histomorphometry of the secondary spongiosa in distal femur and femoral shaft. (
tissue volume (BV/TV, %), trabecular bone thickness (Tb.Th, μm), trabecular number (Tb. N.,/mm
surface/bone surface (OS/BS, %), and osteoid thickness (O.Th, μm). Osteoblast surface/bone surfa
(Oc N./B. Pm,/100 mm), osteoclast surface/bone surface (Oc.S/BS, %), mineral apposition rate (M
bone surface (BFR/BS, mm3/mm2/year). ND: not detected. (a) p b 0.05 vs. Sham, (b) p b 0
(B) Histomorphometry of femoral shaft. ND: not detected. (a) p b 0.05 vs. Sham, (b) p b 0
(C) Representative pictures of double labeling with tetracycline hydrochloride and calcein.reported (Furuya et al., 2011). Teriparatide was provided from
Asahikasei Pharmaceutical Co. Ltd. (Tokyo, Japan). Twelve-week-old vir-
gin female C57BL/6Nmicewere purchased fromSankyo Labo ServiceCo.
(Tokyo, Japan). All mice were housed under speciﬁc pathogen-free
conditions and exposed to a 12-h light–12-h dark cycle and treated
with humane care under the approval of the Animal Care and Use
Committee of the University of Tokyo.
2.2. Treatment protocols
The study design is shown schematically in Fig. 1. Mice were
assigned to ﬁve different groups. Four groups were ovariectomized
(OVX) and one group was sham operated (Sham). Four weeks after
the surgeries, mice in the OVX groups were either untreated (OVXA) Histomorphometry of distal femur. Histomorphometric parameters: the bone volume/
), trabecular bone separation (Tb.S., μm), osteoid volume/bone volume (OV/BV, %), osteoid
ce (Ob.S/BS, %), eroded surface/bone surface (ES/BS, %), osteoclast number/bone perimeter
AR, μm/day), mineralizing surface per bone surface (MS/BS, %), and bone formation rate/
.05 vs. OVX, (c) p b 0.05 vs. Ab, (d) p b 0.05 vs. PTH. Data are mean ± SD (n = 3–4).
.05 vs. OVX, (c) p b 0.05 vs. Ab, (d) p b 0.05 vs. PTH. Data are mean ± SD (n = 3–4).
Fig. 5 (continued).
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teriparatide (80 μg/kg/day for 4 weeks) (PTH group), or antibody plus
PTH (Ab + PTH group). All mice were sacriﬁced 8 weeks after the
operation. Sera was obtained using capillary blood collection tube
with serum separator (Becton, Dickinson and Company, Sparks, MD),
and concentrations of C-telopeptide (CTx) (RatLaps ELISA; Nordic
Bioscience, Herlev, Denmark) and osteocalcin (mouse osteocalcin EIA,
Biomedical Technologies Inc., Stoughton, MA) were measured.2.3. Radiological analysis
Micro CT scanning of the distal femur was performed using a
ScanXmate-L090 Scanner (Comscantechno Co., Ltd., Yokohama,
Japan). Three-dimensionalmicrostructural image datawere reconstruct-
ed and structural indices were calculated using TRI/3D-BON software
(RATOC Systems, Osaka, Japan). BMD in the femur and lumbar spine
was measured using a bone mineral analyzer (PIXImus Densitometer;
GE Medical Systems, Waukesha, WI).2.4. Histological and histomorphometric analysis
For histological analysis, ﬁxed and undecalciﬁed femurs were
embedded in glycol methacrylate, and 3 μm sections in the distal
femur were longitudinally cut and stained with toluidine blue (TB) or
tartrate-resistant acid phosphatase (TRAP). Histomorphometric
measurements were made at ×400 magniﬁcation in the secondary
spongiosa area of distal femur. For double labeling, mice were injected
subcutaneously with 20 mg/kg body weight of tetracycline hydrochlo-
ride on day 4 and 16 mg/kg body weight of calcein on day 1 before
sacriﬁce.2.5. Statistical analysis
Each series of experiments was repeated at least three times. The
results are expressed as the mean ± SD. Statistical analyses were per-
formed using a two-tailed unpaired Student's t test or ANOVA analysis.3. Results
3.1. Effects of anti-RANKL antibody and PTH on OVX mice
In the distal femur, Ab and PTH groups showed a signiﬁcant increase
in BMD compared to OVX group and Ab+ PTH group exhibited a great-
er increase than Ab and PTH groups (Fig. 2B). The additive effect of Ab
and PTH was conﬁrmed by micro CT analysis (Fig. 2A). In contrast,
PTH and Ab + PTH treatment exhibited a signiﬁcant increase in BMD
in the femoral shaft, which was not observed in Ab group (Fig. 2C). In
the lumbar spine, Ab and Ab + PTH groups showed a signiﬁcant
increase in BMD (Fig. 2D).
We then analyzed the serum bone turnover markers, CTX-I and
osteocalcin, 8 weeks after ovariectomy. Serum CTX-I levels were signif-
icantly suppressed in Ab group and increased in PTH group compared to
OVX group. CTX-I levels were also suppressed in Ab + PTH group, and
no signiﬁcant difference was observed between Ab and Ab + PTH
groups (Fig. 3A). Osteocalcin levels were signiﬁcantly higher in PTH
groups than OVX group, but no signiﬁcant change was observed in Ab
and Ab + PTH groups (Fig. 3B). These results indicate that the bone
turnover is maintained at low levels by anti-RANKL antibody treatment
even after PTH treatment.
3.2. Histology and histomorphometry
As shown in Fig. 4 by toluidine blue staining of the distal femur, Ab
treatment and PTH treatment increased BMD at the distinct regions.
Ab treatment mainly increased BMD in the primary spongiosa region,
while PTH increased that in the secondary spongiosa. Ab + PTH treat-
ment increased BMD in both primary and secondary spongiosa regions
(Fig. 4). TRAP staining of the distal femur showed a marked decrease in
osteoclasts in Ab and Ab + PTH groups and increase in PTH group
(Fig. 4). Histomorphometric analysis in the trabecular bone in the distal
femur demonstrated a signiﬁcant increase in BV/TV in Ab and PTH
groups, and the combination of Ab and PTH exhibited an additive effect.
Ab treatmentmarkedly decreased osteoblast parameters such as OV/BV,
OS/BS, Ob.S/BS, MAR, MS/BS, and BFR/BS as well as osteoclast parame-
ters such as ES/BS, OcN/BS, and Oc.S/BS, and these parameters remained
Fig. 5 (continued).
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bone region (femoral shaft), marked increase in MAR and MS/BS was
observed by PTH treatment in the periosteal surface, whichwas strong-
ly suppressed by combination treatment with Ab. In contrast, in the
endosteal surface, signiﬁcant reduction in MAR, MS/BS, and BFR/BS
was observed in Ab-treated mice, which was not recovered by treat-
ment with PTH (Fig. 5B). Representative data of double labeling are
provided in Fig. 5C.
4. Discussion
The usefulness of combination therapy of anti-resorptives with ana-
bolic agents in osteoporosis patients is still controversial. Previous stud-
ies have demonstrated that combination with bisphosphonates such as
alendronic acid and zoledronic acid does not exert additive effects on
PTH-induced increase in BMD in the clinical setting (Black et al., 2003;
Finkelstein et al., 2003; Cosman et al., 2011; Li et al., 2012). This is at
least partly because suppression of bone resorption inhibits bone
resorption-dependent release of coupling factors from bone matrix.However, several animal studies showed that PTH exhibits anabolic ef-
fects even in the presence of anti-resorptives. Pierroz et al. (2010) dem-
onstrated that treatment of RANK−/− mice, which completely lack
osteoclasts, with high dose PTH still increased serum osteocalcin and
trabecular BMD. In addition, recent clinical study showed that
denosumab and PTH had additive effects on BMD (Tsai et al., 2013).
We previously reported that a single subcutaneous injection of anti-
RANKL antibody OYC1 markedly augmented BMD in normal mice. We
here analyzed the effect of combination treatment of intermittent PTH
and anti-RANKL antibody in ovariectomized mice (Furuya et al.,
2011). Consistent with the recent clinical results of combined PTH and
denosumab treatment, we found that Ab had additive effects on PTH
in BMD increase in the distal femur. In contrast, Ab did not appear to in-
crease BMD of femoral shaft, or have additive effects on PTH, indicating
that the additive effects of Ab on PTHwere only observed in the trabec-
ular bone. Interestingly, histological analysis exhibited that these two
reagents increased BMD at distinct regions. Ab mainly increased BMD
at the primary spongiosa region, while PTH did so at the secondary
spongiosa region. The combination of Ab and PTH increased both
7N. Tokuyama et al. / Bone Reports 2 (2015) 1–7primary and secondary spongiosa regions. In addition, at the cortical
regions, PTH increased bone formation at the periosteal surface but
not at the endosteal surface, which was completely suppressed by Ab.
PTHdid not increase bone formation or bone resorption at the endosteal
surface, while Ab treatment suppressed both bone formation and bone
resorption. These results suggest that these two reagents have distinct
properties in the function of increasing BMD, in particular, their target
regions. Pierroz et al. (2010) showed that combined treatment of PTH
with denosumab in human RANKL transgenic mice did not have addi-
tive effects on BMD as compared to denosumab alone. They discussed
that this may be because too much suppression of bone resorption im-
pairs the anabolic effects of PTH. Although the reason for the discrepan-
cy between their results and our data is not clear, we speculate that the
bone dynamics in human RANKL transgenic mice may be somehow
different from that in OVX mice.
We found that Ab and PTH increased BMD at the distinct regions of
the distal femur, primary spongiosa, and secondary spongiosa, and the
combination of Ab and PTH increased BMD in both of these regions. In
addition, PTH, but not Ab, increased periosteal bone formation, and
Ab treatment suppressed PTH-induced periosteal bone formation. Con-
sistent with this observation, there were no additive effect of Ab on
PTH-induced BMD increase in the femoral shaft. There are limitations
in the present study. In particular, this is a mouse study, and it may
not be directly applied to humans. In addition, molecular basis of the
site-speciﬁc effect of Ab and PTH is not clear. Future human study will
reveal the effect of the combination therapy on the skeletal tissues in
a further detail.
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